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Introduction
The advent of next-generation sequencing (NGS) technolo-
gies has dramatically reduced costs and thus democratized 
sequencing1. Consequently, both big research consortia and 
small laboratories now have the ability to utilize large-scale 
genomic applications such as RNA sequencing (RNA-Seq) for 
transcriptome profiling. However, while sequencing cost is 
on the decline, the cost of data storage, analysis and inter-
pretation is increasing1. Major challenges for analyses of 
RNA-Seq data include the need for a substantial informatics 
hardware and software infrastructure as well as a wide range of 
computational skills to effectively manage and process the data. 
With the plethora of published bioinformatics software, data 
formats, and human genome information, careful bioinformat-
ics workflow development, parameterization, reference dataset 
management, and execution are required to generate consistent, 
reproducible and high-quality analysis datasets2. Interpretation 
of RNA-Seq data requires special statistical and visualization 
techniques3,4. In addition, most of the NGS bioinformatics 
software only runs on the Linux operating system (OS) or is 
dependent on Linux tools/utilities. These requirements limit the 
ability of small labs and individual principal investigators to ana-
lyze such data, in particular, those that use desktop computers 
running non-Linux based OS with limited IT support. Emerg-
ing information technologies, bioinformatics workflow engines, 
and open-source analytical modules are presenting opportunities 
to reduce this burden5. Virtualization technologies, for example, 
now allow entire OS replete with all the necessary software 
packages to be archived and then instantiated just about anywhere 
at a moment’s notice, independent of the hardware architecture 
available. For instance, all software components and dependen-
cies can be encapsulated within Virtual Machines (VMs). These 
characteristics of virtual appliances allow users to choose the 
number and size of VMs to be provisioned and thus provide 
on-demand computational scalability. Commercial cloud service 
providers such as Amazon Web Services, Google Cloud Platform, 
and Windows Azure provide user-friendly web-based tools to 
manage VMs and associated computational resources, includ-
ing cloud storage, networking, security, identity management, 
and backup and disaster recovery. This pay-as-you go model 
eliminates upfront capital expenses by converting the budget-
ing representation of bioinformatics processing tasks and storage 
into well-defined operational costs. The open-source R statisti-
cal programming language in combination with the Bioconductor 
package resource provides researchers with a consistent way 
to share and use specialized statistical methods for RNA-Seq 
analysis6,7. In combination with the R knitr package, analysis 
data sets can be processed automatically using R and summarized 
in reports by integrating formatting instructions with analytical 
components8. Together, these technologies can reduce analysis 
time and programming effort, allow more accurate estimation 
of hardware costs, improve quality of results, and facilitate 
reproducible research by transparently documenting all steps 
including software and OS.
RNA-Seq allows snapshot measurements of the human transcrip-
tome by partially sequencing reverse-transcribed RNA transcripts 
(cDNA) expressed in cell populations or single cells of interest. 
In the context of clinical trials, the goal of transcriptomics studies 
is to identify and better understand changes in cell states on the 
gene expression level that can be attributed to a certain treat-
ment (e.g., a vaccine or drug)9,10, or changes that can predict 
individual treatment responses (e.g. the likelihood of developing 
protective levels of antibody)11,12. The number of RNA-Seq reads 
(short DNA sequence) corresponding to a transcript has been 
shown to be linearly associated with true transcript abundance 
spanning a large quantitative range13. Prior to gene expression 
quantification, processing of human RNA-Seq data requires a com-
putationally intensive alignment step that maps sequence reads 
against the human reference transcriptome and/or genome 
sequence14–16. Resulting alignment metrics including genomic 
mapping locations (chromosome and position), alignment 
information (insertions, deletions, and matching bases), align-
ment quality scores, among other information, are recorded in the 
form of Binary Alignment Mapping (BAM) files17. Various algo-
rithms have been developed that use this mapping information for 
determining/counting which sequence read originated from a 
certain gene, gene isoform, or gene exon18–23. Following gene 
expression quantification, key analysis steps include the detec-
tion of treatment-responsive genes (e.g. 4) and subsequent 
characterization of these genes using pathway enrichment 
analysis (e.g. 24). Challenges prior to RNA-Seq data interpre-
tation include (1) estimation of expected cost for storage and 
data processing, (2) provisioning of computational resources 
for storage and data processing, (3) installation of Linux OS, 
required bioinformatics software, and reference data sets, 
(4) suitable analytical methods including advanced data visualiza-
tions to summarize key tends in the data, and (5) automation and 
documentation of all steps to facilitate reproducible research.
In this article, we summarize the RSEQREP framework we 
developed that allows researchers to address these challenges 
and to streamline the transition from a desktop environment to a 
server-based scalable cloud infrastructure using Amazon Web 
Services (AWS). Alternatively, the framework can be installed on 
a local Ubuntu machine via installation scripts that we provide. 
We exemplify the framework’s capabilities using RNA-Seq data 
generated for an influenza vaccine study that extracted RNA 
from peripheral blood mononuclear cells (PBMCs) and B-cells 
samples collected from 5 subjects prior to trivalent influenza 
vaccine (TIV) vaccination and at 10 time points post TIV vaccina-
tion (days 1-10) (GEO accession: GSE45764, Dataset 1,10).
Methods
Implementation
Figure 1 provides an overview of RSEQREP software compo-
nents. The framework is organized into four main components: 
(1) reference data setup, (2) pre-processing, (3) analysis, and 
(4) reporting. The pre-processing component uses a combination 
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Figure 1. RNA-Seq Reports (RSEQREP) implementation overview. RSEQREP provides a reproducible start-to-end analysis solution 
for RNA-Seq data by automating (1) reference dataset initialization/download, (2) RNA-Seq data processing (3) RNA-Seq analysis, and 
(4) reporting including a summary PDF report and publication-ready table and figure files. Steps can be run in a modular fashion and key 
computational metrics are tracked in a SQLite database. The software runs on a pre-configured RSEQREP AMI or on a local Ubuntu Linux 
machine. Users can customize individual steps and enter their experimental design information via an Excel configuration file.
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of open-source software, shell, R, and Perl scripts and a SQLite 
relational database to process raw sequence data, quantify gene 
expression, and track storage, file check-sums, CPU, memory, 
and other runtime metrics. The analysis component is based on R 
using both custom R programs, as well as existing R/Bioconductor 
packages. The reporting component is based on R, the knitr 
R package, and LaTeX for reproducible and automatic PDF 
report and figure/table generation. All components read user- 
defined arguments from the respective tab in the RSEQREP 
configuration spreadsheet (RSEQREP/config/config.xls).
Operation
All four workflow components can be run in sequence 
via the RSEQREP/run-all.sh script or run individually to 
update results of the respective component. When running each 
individual step, the most recent version of the configuration file 
will be reloaded to ensure that any modifications to the configu-
ration will be reflected. This is particularly useful for optimizing 
results and customizing result presentation, for example, by 
removing outliers, optimizing the low-expression cut-off, or 
adjusting the color-coding range for heatmaps. In the fol-
lowing, we provide an overview of each of these steps. 
Additional information can be found in the method section 
of the RSEQREP summary report (Supplementary File S1).
Step 1) Reference Data Set-up. The RSEQREP/setup.sh script 
reads all user-specified arguments provided in the config.xls file, 
downloads all required reference data including user-specified 
versions of the human reference genome sequence and associated 
gene model information from the Ensembl database25. Input for 
pathway enrichment analysis is handled via Gene Matrix Trans-
posed (GMT) files. For GMT files, Entrez Gene IDs, Ensembl 
Gene IDs, or gene symbols are supported and will be automati-
cally mapped to the human Ensembl reference annotations. We 
recommend that users obtain reference pathway GMT files from 
the Molecular Signatures Database (MSigDB)26. The MSigDB 
import is not automated as download requires registration but 
the location of downloaded GMT file can be specified in the 
configuration file. We do provide a script (RSEQREP/source/shell/
download-gene-sets.sh) to automatically download Reactome, 
Blood Transcription Module27, and KEGG pathway information 
and convert this information to GMT files (note, a license may 
be required prior to downloading KEGG pathway information). 
Following the reference dataset download, an index of the 
human reference genome sequence will be created to optimize 
reference alignment searches15,16. Result files generated as part of 
this step are saved under the data output directory.
Step 2) Data Pre-processing. Based on FASTQ file input 
specifications in the config.xls, the RSEQREP/run-pre-processing.sh 
script downloads and decrypts (optional) FASTQ files hosted on 
AWS Simple Storage Service (S3) storage (https://aws.amazon.
com/s3), a local file location (Linux file path), or directly from 
Sequence Read Archive (SRA)29 via FTP URLs. Following the 
download, the script executes sequence data QC (FastQC), ref-
erence genome alignments (STAR16 or Hisat215 splice-aware 
aligner on stranded, unstranded, or paired-end read data as 
specified in the config.xls), reference based compression to gener-
ate storage-optimized CRAM files (SAMtools17), gene expression 
quantification (featureCounts as implemented in subread18), and 
reference genome alignment QC (RSeQC30). Additionally, the 
script tracks program arguments, program return codes, input and 
output file names, file sizes, MDS checksums, wall clock times, 
CPU times and memory consumption in a SQLite relational data-
base. Interim result files generated as part of this step are saved 
under the specified pre-processing output directory.
Step 3) Data Analysis. The RSEQREP/run-analysis.sh script 
initializes analysis datasets for the final reporting step including 
(1) TMM-normalization31 and exclusion of low-expressed 
genes, (2) principal component analysis (PCA), distance matrix 
calculations for non-metric multidimensional scaling (MDS), and 
hierarchical clustering for global multivariate analyses, (3) log2 
fold change calculations used as input for heatmap and co- 
expressed gene-cluster analyses, (4) identification of differentially 
expressed (DE) genes (edgeR32), co-expressed gene clusters 
(pvclust33), and enriched pathways (GoSeq24). Interim result 
files generated as part of this step are saved under the specified 
report output directory.
Step 4) Automatic Report Generation. The RSEQREP/run-report.sh 
script produces the final results. It runs R analyses on the inter-
mediate analysis files generated in Step 3, generates a summary 
PDF report using the knitr R package in combination with LaTeX, 
and result tables in gzipped .csv format as well as individual 
figure files in .pdf, and .png format. This script also summarizes 
key run time statistics that were collected as part of Step 2. 
Result files generated as part of this step are saved under the 
specified report output directory.
Minimal system requirements
A 35 GiB Elastic Block Store (EBS) volume, i.e. storage 
immediately accessible to the OS (http://docs.aws.amazon.com/ 
AWSEC2/latest/UserGuide/EBSVolumes.html), sufficiently covers 
space for the OS, user accounts, reference data, and to process 
and analyze dataset sizes similar to that of the influenza vaccine 
case study when CRAM compression is deactivated. To 
accommodate storage for CRAM-compressed files and studies 
with larger sample sizes and/or sequence coverage, additional 
EBS volumes are required (see information on AWS set-up under 
RSEQREP/aws/aws-setup.docx).
We found that a c3.xlarge computational Elastic Compute Cloud 
(EC2) instance type (4 vCPUs, 7.5 GiB, https://aws.amazon.com/
ec2/instance-types) is sufficient for data processing and analysis, 
but a higher memory machine (c3.4xlarge: 16 Gib for HISAT2 
and c3.8xlarge: 37 Gib for STAR) is required to successfully 
complete the indexing of the reference genome sequence as part 
of Step 1.
Installation
We provide a pre-configured RSEQREP Amazon Virtual Machine 
Image available on AWS at (https://aws.amazon.com, AMI ID: 
RSEQREP (RNA-Seq Reports) v1.0 (ami-e1708b9b)) that com-
bines the Ubuntu operating system Version 16.04.2 (long-term 
support) with all additional software that is required for RSEQREP 
operation (RSEQREP/SOFTWARE.xlsx). We prepared a manual 
that provides instructions on how to set-up an AWS instance 
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including mounting of EBS volumes for local storage and an 
optional Elastic IP address for machine access (RSEQREP/aws/
aws_instructions.docx). Alternatively, we provide installation 
scripts that can be executed on a local Ubuntu machine 
(Version 16.04.2) to install necessary dependencies (RSEQREP/ 
ubuntu/install-software.sh). In both cases, AWS and local set-up, 
prior to workflow execution, users would need to pull the 
latest RSEQREP source code from GitHub (git clone https:// 
github.com/emmesgit/RSEQREP).
Configuration
RSEQREP configuration is handled via the RSEQREP/config/ 
config.xlsx file. The first tab allows users to specify sample 
metadata. Fields include subject ID, sample ID, sampling time 
point, a flag (is_baseline) that indicates if a sample was col-
lected prior to treatment, the treatment group, specimen type (e.g. 
B-cells, PBMCs, etc.), and FASTQ sequence file location (AWS S3, 
local, or remote SRA location). In addition, color-coding for time 
points, treatment groups, and specimen types can be defined. The 
second tab specifies options related to the pre-processing step. This 
tab uses a two-column key value pair format to define options. 
For example, to specify the Ensembl database version 74, users 
can set the version value via the ensembl_version key value pair 
to 74. Other options include the type of RNA-Seq data (stranded: 
yes/no) and reference alignment software (Star or Hisat2). 
Paired-end experiments can be accommodated for each 
sample by specifying two input FASTQ files. The third tab 
allows users to customize analysis and reporting components. 
Options include specification of cut-offs to define lowly-expressed 
genes, DE genes, and enriched pathways, as well as the distance 
metric and hierarchical clustering algorithm used for heatmap 
and gene clustering analysis. For further information, see descrip-
tions and examples for each of these options in the influenza 
vaccine case study configuration file (Supplementary File S2). 
We implemented the framework to dynamically adjust the report 
presentation depending on the number of subjects, time points, 
specimen types, and treatment group combinations. For exam-
ple, Venn diagrams are shown for comparisons between up to 
five sets (e.g. five time points). Larger sets are accommodated 
via UpSet plots34. The configuration file allows users to carry out 
subgroup analysis by limiting the metadata file to samples, 
treatment groups, and time points of interest.
Use Case
To illustrate the capabilities of RSEQREP, we analyzed a pub-
licly available RNA-Seq dataset comprising 110 RNA-Seq 
samples: five subjects, 11 time points (pre-vaccination and 
days 1-10 post-vaccination), two specimen types (PBMCs and 
B-cells), and one treatment group (Trivalent Influenza Vaccination 
(TIV)) (GEO accession: GSE45764, Dataset 1,10). The unstranded 
single-end RNA-Seq experiment was carried out with a read 
length of 65 nt (nucleotides) and an average sequence coverage of 
16 million total mapped reads. The study was designed to obtain 
detailed information on the early temporal gene expression response 
following TIV vaccination in both PBMC and B-cells. The con-
figuration file that specifies the case study experimental design, 
public SRA FASTQ FTP URLs, data processing and analysis 
parameters is provided in Supplementary File S2. The configura-
tion file allows users to reproduce RSEQREP results for this case 
study on their own RSEQREP AWS instance or Ubuntu Linux 
machine. Supplementary File S1 represents the corresponding 
RSEQREP Summary PDF report, including 131 figures and 135 
tables. In the following, we describe a subset of key findings 
(referenced supplemental tables and figures refer to the 
corresponding results in the supplemental PDF report). See 
Supplementary File S1 methods for additional information on pre-
processing and analysis steps.
Global gene expression patterns and DE gene time trends
PCA results revealed that most variation in gene expression based 
on standardized log2 counts per million across all 110 samples 
was attributable to cell type (B-cells vs. PBMCs, Figure 2). In 
addition, two extreme outliers, including one B-cell sample 
that was likely mislabel as a PBMC sample, were identified. 
These samples were added to the configuration file as outliers 
to be excluded from downstream analysis. Negative binomial 
models as implemented in the edgeR package32 were fit to iden-
tify genes that were DE compared to pre-vaccination at each of 
the post-vaccination days. UpSet plots visualizing the number and 
overlap of DE genes over time are presented in Figure 3. PBMCs 
showed overall peak DE responses at day 1 (24 hours after TIV 
vaccination) with 136 genes being DE compared to pre-treatment 
gene expression levels. Between days 1–4, PBMC DE signals 
declined followed by a broader second peak response for 
days 5–8 reaching the second highest response of 96 DE genes at 
day 6. While most DE genes in PBMCs at day 1 were unique (106 
of 136 genes (78%)), most DE genes at day 6 (64 of 96 (67%)) 
were overlapping with other DE gene responses, in particular, with 
days 5, 7, and 8. In contrast to PBMCs, B-cells did not 
exhibit a noticeable DE gene signal at day 1, but showed 
responses between days 5–8 (121–481 genes) reaching high-
est responses at day 6 (481 genes). While some DE genes were 
unique to day 6 (168 of 481 (35%)), many were shared with 
day 7 (124 genes), as well as day 7 and day 8 (72 genes). For 
both cell types, most DE genes were up-regulated from pre- 
vaccination (Figure 3, middle panel vs. right panel). Most of 
the overlap between PBMC and B-cell DE genes was observed 
at day 6, at which 62 of 96 DE PBMC genes (65%) were also 
reported as DE in B-cells (Figure S35). Tables S7–S26 list 
individual DE gene results. In the following, pathway enrich-
ment analysis results for peak DE responses and a selection of 
identified co-expressed gene clusters are summarized.
Pathway enrichment analysis results
To functionally characterize DE gene responses, pathway enrich-
ment analysis as implemented in the GoSeq R package24 was 
carried out using MSigDB (Version 5.2, Dataset 2) and Blood 
Transcription Modules (Dataset 3) reference gene sets/pathways. 
Pathway enrichment analysis of the day 1 peak DE gene signal 
in PBMCs identified innate immune response signaling pathways 
including Reactome-based interferon signaling, in particular, 
interferon gamma signaling and interferon alpha/beta signaling 
(Figure 4, Table S97). Top enriched GO Biological processes 
included innate immune response, defense response to virus and 
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Figure 2. Global gene expression pattern analysis to identify outliers and batch effects (influenza vaccine case study). RSEQREP 
supports multivariate visualizations, including principal component analysis (PCA) to visualize key trends in the data. The analysis uses 
standardized log2 counts per million (mapped reads) for genes that met the low expression cut off as input. As shown for the influenza 
case study, the PCA analysis indicated that PBMC (highlighted in red) and B-cell (highlighted in blue) samples differ substantially in their 
transcriptional profiles. In addition, two outliers were identified in relation to the other samples (highlighted in blue circles). Ellipses represent 
the 95% confidence interval for the bivariate mean based on the first two principal components by specimen type.
response to type I interferon (Table S92). The top Blood Transcrip-
tion Modules indicated that day 1 PBMC DE genes were most 
preferentially enriched in monocytes (II) (M11.0) but also 
enriched in activated dendritic cells (II) (M165), and enriched in 
neutrophils (I) (M37.1) (Table S91). The day 6 PBMC DE gene 
signal was related to plasmablast and B-cell Blood Transcrip-
tion Module signatures including plasma cells, immunoglobulins 
(M156.1), plasma cells, and B cells, immunoglobulins (M156.0), 
and enriched in B-cells (II) (M47.1) (Table S115). The day 6 
peak DE gene response in B-cells was enriched in several cell 
cycle-related pathways including Reactome cellcycle mitotic, 
cellcycle and DNA replication (Figure 4, Table S73). In 
addition, processes involved in protein-processing such as GO 
Cellular Component endoplasmic reticulum part and endoplasmic 
reticulum (Table S69) and GO Biological Process protein 
complex assembly and intracellular protein transport (Table S68), 
as well as Reactome metabolism of proteins, post-translational 
protein modification, and asparagine N-linked glycosylation were 
identified (Figure 4, Table S73). Enrichment results based on 
Blood Transcription Modules confirmed enrichment of cell cycle-
related modules but also identified several plasma cell-related 
signatures such as plasma cells surface signature (S3), plasma 
cells, and B cells, immunoglobulins (M156.0), and plasma cells, 
immunoglobulins (M156.1) (Table S67). The top most enriched 
MSigDB Immunological Signature was related to genes that were 
up-regulated at day 7 following TIV vaccination compared 
to pre-vaccination in a previous influenza vaccine study by 
Nakaya et al. (GEO accession: GSE29614, 35) (Table S70). 
Tables S50–S133 list all pathway enrichment analysis results.
Co-expressed gene cluster results
To identify robust clusters of co-expressed DE genes based on 
correlation between log2 fold change responses, unsupervised 
multi-scale bootstrap resampling as implemented in the pvclust 
R package33 was executed. Several known immuno-globulin 
genes had robustly correlated log2 fold changes across all post- 
vaccination days (day 1–10) in B-cells and PBMCs reaching peak 
mean log2 fold change responses between days 5 and 8 (Figure 5). 
The immunoglobulin gene cluster highlighted for PBMCs 
comprised 7 genes (5 immunoglobulin genes: IGHG1, IGHG3, 
IGHGP, IGKC, IGKV3-11 and 2 genes not encoding for immu-
noglobulins: MZB1, and TNFRSF17) (Figure 5 bottom right). 
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Figure 3. UpSet plots to summarize key differentially expressed (DE) gene time trends (influenza vaccine case study). These panels 
summarize the DE gene overlap between post-treatment days for up- or down-regulated DE genes (shown to the right in black), for up-
regulated DE genes (shown in the middle in red), and down-regulated DE genes (shown to the right in blue), respectively within specimen 
type (B-cells are shown in the top row, PBMCS in the bottom row). In each panel, the bottom left horizontal bar graph labeled SDEG Set Size 
shows the total number of DE genes per post-treatment time point. The circles in each panel’s matrix represent what would be the different 
Venn diagram sections (unique and overlapping DE genes). Connected circles indicate a certain intersection of DE genes between post-
treatment days. The top bar graph in each panel summarizes the number of DE genes for each unique or overlapping combination. In the 
top left panel, for example, the first vertical bar/column shows those DE genes that are unique to day 6 (168 DE genes). The second shows 
those DE genes that are shared only between days 6 and 7 (124 DE genes). The third are those DE genes that are shared between days 6, 
7, and 8 (72 DE genes), and so forth. As shown for the influenza case study, most of the DE genes for B-cells were detected and overlapped 
between days 6, 7 and 8 while most of the DE genes for PBMCs were uniquely identified at day 1.
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Figure 4. Heatmaps for visualizing pathway enrichment over time (influenza vaccine case study). Reactome pathways that were 
enriched in at least two conditions are shown. Cells are color-coded by enrichment score: -1 x log10(FDR-adjusted p-value). Cell values 
represent the number of DE genes that overlap with a certain pathway. Numbers in brackets indicate enriched pathways, i.e. pathways that 
met the specified FDR-adjusted p-value cut off. Pathways were clustered based on enrichment score. As shown for the influenza case study, 
pathways related to cell-cycle as well as protein metabolism were enriched in B-cells at day 6. Both, B-cell and PBMCs showed an enrichment 
of interferon signaling-related pathways at day 1.
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Figure 5. Co-expressed gene cluster time trends (influenza vaccine case study). RSEQREP supports unsupervised multiscale bootstrap 
resampling to identify co-expressed gene clusters based on their log2 fold change pattern over time. A subset of trends is shown for the 
influenza case study. Several co-expressed immunoglobulin genes reached peak log2 fold changes compared to pre-treatment between day 
6 and 7 while a cluster of interferon-induced antiviral (IFIT) genes showed an earlier peak in log2 fold change at day 1 in addition to a peak 
at day 8 in PBMCs.
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MZB1 is known to play a role in IgM assembly and secretion 
while TNFRSF17 is known to regulate humoral immunity 
including plasma cells. Several known interferon-inducible genes 
co-expressed in PBMCs (IFIT1, IFIT2, and IFIT3) showed an 
initial peak in log2 fold change response at day 1, which declined 
to pre-vaccination levels by day 4, followed by a second higher 
peak response at day 8 (Figure 5 bottom left). Time trends for all 
identified gene clusters are shown in Figures S79–S86.
Discussion
There is an increasing trend towards more open and transparent 
research including increasing demands for sharing of source code, 
software snapshots as well as enhanced scalability to facilitate 
processing of increasingly larger datasets. A plethora of open-
source software for RNA-Seq data processing and analysis has 
been developed4,36,37. The strength of the RSEQREP framework 
is its start-to-end open-source solution that combines operating 
system, bioinformatics software, reference data set-up, data 
processing, analysis, advanced data visualizations, and automatic 
reporting. The resulting RNA-Seq PDF reports can easily be 
customized, extended, and shared.
RSEQREP supports the reproducible research paradigm via its 
pre-configured AMI, open-source components, user-friendly 
configuration file, and functionality to rerun analyses from 
start-to-end or in parts. Using the default RSEQREP AMI, in addi-
tion to on-demand scalable computational resources, has the benefit 
of integrating the operating system and all software installations 
as part of analysis snapshots referenced in the report, providing 
for complete transparency and full reproducibility of all compo-
nents involved. In addition, the software tracks computational 
runtime metrics (CPU and memory consumption), which can 
be used to track and estimate computational cost. Towards that 
end, we benchmarked the preprocessing step for the influenza vac-
cine case study data (110 samples) using increasingly powerful 
but also more expensive AWS EC2 instance types: c3.xlarge 
(4 vCPUs; 7.5 Gib RAM), c3.2xlarge (8 vCPUs; 15 Gib 
RAM), c3.4xlarge (16 vCPUs; 30 Gib RAM), and c3.8xlarge 
(32 vCPUs; 60 Gib RAM). We found that the c3.2xlarge 
(8 vCPUs; 15 Gib RAM) machine marks the ideal convergence 
of processing time and cost (Figure 6).
RSEQREP includes a collection of best practice analytical 
tools that we identified through extensive review of the peer-
reviewed literature. This includes TMM-normalization to 
remove systematic differences between samples31, filtering of 
lowly expressed genes to improve accuracy of fold change esti-
mates and power of DE detection, application of statistical 
methods that model read count variability using a discrete nega-
tive binomial distribution and share information across genes32, 
the use of moderated log2 counts per million for multivariate 
analyses, and adjustment for gene length bias38 as part of pathway 
enrichment analysis39. In addition, the software provides several 
unique visualizations, including multivariate starplots for refer-
ence alignment QC (Figures S2), co-expressed gene cluster time 
trends (Figure 5), as well as pathway enrichment heatmaps 
(Figure 4) and radar plots (Figure S117).
RNA-Seq data processing and analysis is a constantly evolving 
field and there is no consensus on how to best analyze the data. 
For example, RSEQREP summarizes gene expression on the 
gene level - a widely used robust gene expression quantification 
approach18,19. However, methods that support expression quan-
tification on the gene-isoform level have been developed20–23. 
Depending on the research question, RNA-Seq analysis may 
include novel transcript/splice junction discovery, determina-
tion of single nucleotide polymorphism (SNPs), detection of 
RNA-editing events, and fusion genes40. In addition, several 
other popular DE gene detection algorithms such as DESeq2 
exist41. While such additional analysis choices are currently not 
implemented in RSEQREP, the key advantages of this frame-
work are that users have complete access to the source code to 
make custom updates to all workflow, analysis, and reporting 
components. In combination with scalable cloud resources this 
allows for rapid prototyping of analysis reports.
Using RSEQREP on published RNA-Seq data of an influenza 
vaccine study10, we confirmed key transcriptional events in 
PBMCs and B-cells following TIV vaccination10. Three of five 
subjects in this study had reported previous influenza vaccinations. 
A memory response was confirmed by the RSEQREP analysis, 
which identified an early plasma cell and cell proliferation sig-
nature in B-cells with a peak 6 days following vaccination. This 
signal included cluster responses for several co-expressed immu-
noglobulin genes as well as an up-regulation of genes preferen-
tially involved in protein assembly, protein transport, ER-related 
pathways – all of which are at the core of antibody-generating cel-
lular machinery. While not as strong as for B-cells, a peak day 6 
plasma cell signature and co-expressed immunoglobulin gene 
response was also identified in PBMCs. This makes sense as 
B-cells are included in bulk PBMCs. PBMCs showed a strong 
up-regulation of an innate immune signaling responses 24 hours 
post-vaccination, in particular, responses related to interferon 
signaling. This signaling response was enriched in monocyte, 
dendritic cell, and neutrophil-specific gene expression signa-
tures indicating that it was driven by the innate immune cell 
subset within PBMCs. Several co-expressed genes in the IFIT 
gene family were significantly up-regulated at day 1. These 
genes are known to be activated following interferon sig-
naling and to exhibit antiviral activity by recognizing  and 
inhibiting viral RNA42,43. This is in agreement with other studies 
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Figure 6. Wall clock time benchmarks for RNA-Seq pre-processing steps by AWS EC2 instance type. Metrics are based on 110 influenza 
case study RNA-Seq samples. The following instance types were used: c3.xlarge (4 vCPUs, 7.5 GiB Mem), c3.2xlarge (8 vCPUs, 15 GiB 
Mem), c3.4xlarge (16 vCPUs, 30 GiB Mem), c3.8xlarge (32 vCPUs, 60 GiB Mem). Median wall clock time is summarized as tracked in the 
RSEQREP SQLite database. The biggest relative reduction in wall clock time across processes was observed when switching from the 4 
vCPU to the 8 vCPU instance type (c3.xlarge vs. c3.2xlarge). Higher core machines (16 and 32 vCPUs) did result in further reduced wall clock 
time for completing reference alignments (HISAT2) and gene expression quantification (Subread) but the change was not as substantial.
that have shown that IFIT genes are up-regulated 24 hours post- 
influenza vaccination12,44.
Data and software availability
RSEQREP source code available from: https://github.com/ 
emmesgit/RSEQREP
Archived source code as at time of publication: DOI is http://doi.
org/10.5281/zenodo.106911445
RSEQREP Amazon Virtual Machine Image available from: 
https://aws.amazon.com, AMI ID: RSEQREP (RNA- Seq Reports) 
v1.0 (ami-e1708b9b))
License: Subject to various licenses, namely, the GNU Gen-
eral Public License version 3 (or later), the GNU Affero General 
Public License version 3 (or later), and the LaTeX Project 
Public License v.1.3(c).
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A list of the software contained in this program, including 
the applicable licenses, can be accessed at https://github.com/ 
emmesgit/RSEQREP/SOFTWARE.xlsx
Dataset 1. RNA-Seq of PBMC and B cell gene expression 
profiles in healthy humans following influenza vaccination 
available from NCBI GEO with accession number GSE45764.
Dataset 2. MSigDB Version 5.2 GMT gene set files used for the 




For MSigDB license terms, please refer to http://software.broad-
institute.org/gsea/license_terms_list.jsp. Users are requested to 
create a login prior to data access:
http://software.broadinstitute.org/gsea/register.jsp?next=index.jsp
Dataset 3. Blood Transcription Modules GMT file used for 
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Is the description of the software tool technically sound?
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Are sufficient details of the code, methods and analysis (if applicable) provided to allow
replication of the software development and its use by others?
Partly
Is sufficient information provided to allow interpretation of the expected output datasets and
any results generated using the tool?
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Are the conclusions about the tool and its performance adequately supported by the findings
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First, the authors state that these pipelines should work on a variety of cloud
architectures, but all they explicitly provide is an AMI for AWS use.  Containerization
through Docker (not an endorsement) or some other containerization protocol should





Second, there are many mentions of bioconductor, but it is not clear from the manuscript
whether this particular pipeline is available in bioconductor.  Please clarify.
RSEQREP is not available as a Bioconductor R package and includes components not written in
R. The source code is available at https://github.com/emmesgit/RSEQREP
Third, given that the components of such pipelines are continuously evolving, there
should be some documentation, either in the manuscript or the github repo about
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The authors have provided a number of useful visualizations including Heatmaps, UpSet
plots, radar plots, and PCA plots, some commonly used plots in RNAseq analysis such as




The generated report includes summary figures for the different analyses and tables with
the list of genes and pathways detected through the analyses. For a large analysis like the
time-series analysis used as an example the generated report includes over 300 pages.
This makes it hard to navigate through the report and find things quickly. Also, it is hard
to explore the DE results by changing log-fold cutoffs, or FDR cutoffs which could easily
be done in a spreadsheet but not in a PDF. The authors might want to consider splitting
the report in two parts, a PDF report with images and summary data and methods, and an








The tool requires users to build the indexes for the database used as the reference
genome. This typically requires a higher memory machine (16 GB for Hisat2, and 37 GB
for STAR). The processing itself can be done with less memory. This could pose a
problem for users trying to run this tool on a typical laptop or workstation. The authors
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 problem for users trying to run this tool on a typical laptop or workstation. The authors
could consider prebuilding some commonly used indices for human, mouse, and rat
genomes so all users do not have to re-index. These references are relatively stable so
the index may only need to be rebuilt once or twice a year. This will ease the burden








The authors have benchmarked their tool on Amazon to identify the most optimal instance
type (Figure 6) so users can minimize costs. The biggest performance gains seem to be
when the machine instance is changed from 4 vCPUs to 8 vCPUs. However, if a user were
to want to use STAR this instance type does not have sufficient RAM. To optimize, the
user will need to either use a larger instance for the entire processing, or launch two
instances, a larger instance for the indexing step, and a smaller instance for processing,




The documentation needs some improvement, particularly if the intended audience is
users with limited computational experience. When I tried to launch the AMI on Amazon I
was not sure what username to use to log into the running instance. Through trial and
error, I figured out that the username was “ubuntu”. But it would be better if this were




Another related issue is that because the pipeline reads Excel config files the user needs
to create the config file on the local machine and upload to the AMI. Most non-tech savvy
users will not necessarily know how to do it easily. The documentation could point to







It appears that the system is only setup for human genome analysis. While editing the
config file it was not clear where to specify the reference genome information for other
organisms. There is no reason the pipeline could not work for other model organisms
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 organisms. There is no reason the pipeline could not work for other model organisms








Once I had the AMI running I had a difficult time executing the test pipeline. I was getting
errors about missing directories or data files. I would recommend that the authors test the
AMI and have clearer instructions on how to download datasets and run the tools in the
AMI. For instance after cloning the github repo I tried running the setup script with the
command “sh RSEQREP/setup.sh” while I was in “/home/ubuntu” and got the following
error:“Fatal error: cannot open file '/home/ubuntu/source/r/parse-rnaseq-configuration.r':
No such file or directory”.
 
I then tried moving to the RSEQREP directory to run the same command and got the error:
 
“File does not exist! /home/ubuntu/msigdb/c2.cp.kegg.v5.2.entrez.gmt.”
 
Based on the error message it appears that the software expects the databases to be
uploaded before the setup script can be run but the documentation does not specify that.
As a result, I was not able to test the VM end-to-end, but with improved testing and
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